Fusion Antibodies PLC
LSE:FAB

Watchlist Manager
Fusion Antibodies PLC Logo
Fusion Antibodies PLC
LSE:FAB
Watchlist
Price: 7.55 GBX -2.58% Market Closed
Market Cap: 7.2m GBX
Have any thoughts about
Fusion Antibodies PLC?
Write Note

Relative Value

FAB doesn't have a meaningful market cap.

The Relative Value of one FAB stock under the Base Case scenario is 4.22 GBX. Compared to the current market price of 7.55 GBX, Fusion Antibodies PLC is Overvalued by 44%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

FAB Relative Value
Base Case
4.22 GBX
Overvaluation 44%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
42
vs Industry
70
Median 3Y
2.8
Median 5Y
3.6
Industry
4
Forward
3.4
vs History
vs Industry
Median 3Y
-3.2
Median 5Y
-8.2
Industry
31.1
Forward
-6.4
vs History
vs Industry
Median 3Y
-4.7
Median 5Y
-21.5
Industry
21.7
vs History
vs Industry
Median 3Y
-4.4
Median 5Y
-14.9
Industry
33.1
vs History
17
vs Industry
45
Median 3Y
3.8
Median 5Y
4.3
Industry
2.6
vs History
42
vs Industry
71
Median 3Y
2.1
Median 5Y
3.3
Industry
3.9
Forward
3.2
vs History
4
vs Industry
63
Median 3Y
5.5
Median 5Y
9.8
Industry
8.8
vs History
vs Industry
Median 3Y
-3.2
Median 5Y
-20.7
Industry
18.9
Forward
-6.2
vs History
vs Industry
Median 3Y
-2.8
Median 5Y
-9
Industry
24.2
Forward
-6.4
vs History
vs Industry
Median 3Y
-4.6
Median 5Y
-19.9
Industry
21.9
vs History
vs Industry
Median 3Y
-4.3
Median 5Y
-12.3
Industry
30.5
vs History
17
vs Industry
37
Median 3Y
5.8
Median 5Y
6.2
Industry
2.4

Multiples Across Competitors

FAB Competitors Multiples
Fusion Antibodies PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Fusion Antibodies PLC
LSE:FAB
7.2m GBP 4 -4.4 -4.5 -4.1
US
PerkinElmer Inc
LSE:0KHE
1.2T USD 451.3 4 598.2 1 607.6 3 591.3
US
Thermo Fisher Scientific Inc
NYSE:TMO
203.4B USD 4.7 32.1 21 29.4
US
Danaher Corp
NYSE:DHR
148.4B USD 6.2 38 22.4 33.3
KR
Samsung Biologics Co Ltd
KRX:207940
71.2T KRW 16.3 67.6 36.6 52.7
CH
Lonza Group AG
SIX:LONN
41.6B CHF 6.3 65.4 34.1 34.1
US
Agilent Technologies Inc
NYSE:A
38.4B USD 5.9 29.8 22.2 25.9
US
IQVIA Holdings Inc
NYSE:IQV
35.1B USD 2.3 25 13.9 21.1
US
Mettler-Toledo International Inc
NYSE:MTD
26.6B USD 6.9 30.9 22.6 25.1
CN
WuXi AppTec Co Ltd
SSE:603259
173.2B CNY 4.5 21.5 15.7 15.7
US
Waters Corp
NYSE:WAT
21.9B USD 7.6 35.3 22.5 27.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
Fusion Antibodies PLC
LSE:FAB
Average EV/EBITDA: 181.9
Negative Multiple: -4.5
N/A N/A
US
P
PerkinElmer Inc
LSE:0KHE
1 607.6
10%
160.8
US
Thermo Fisher Scientific Inc
NYSE:TMO
21
8%
2.6
US
Danaher Corp
NYSE:DHR
22.4
9%
2.5
KR
Samsung Biologics Co Ltd
KRX:207940
36.6
16%
2.3
CH
Lonza Group AG
SIX:LONN
34.1
34%
1
US
Agilent Technologies Inc
NYSE:A
22.2
10%
2.2
US
IQVIA Holdings Inc
NYSE:IQV
13.9
9%
1.5
US
Mettler-Toledo International Inc
NYSE:MTD
22.6
6%
3.8
CN
WuXi AppTec Co Ltd
SSE:603259
15.7
15%
1
US
Waters Corp
NYSE:WAT
22.5
6%
3.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
Fusion Antibodies PLC
LSE:FAB
Average EV/EBIT: 385.6
Negative Multiple: -4.1
N/A N/A
US
P
PerkinElmer Inc
LSE:0KHE
3 591.3
41%
87.6
US
Thermo Fisher Scientific Inc
NYSE:TMO
29.4
24%
1.2
US
Danaher Corp
NYSE:DHR
33.3
20%
1.7
KR
Samsung Biologics Co Ltd
KRX:207940
52.7
22%
2.4
CH
Lonza Group AG
SIX:LONN
34.1
18%
1.9
US
Agilent Technologies Inc
NYSE:A
25.9
16%
1.6
US
IQVIA Holdings Inc
NYSE:IQV
21.1
18%
1.2
US
Mettler-Toledo International Inc
NYSE:MTD
25.1
8%
3.1
CN
WuXi AppTec Co Ltd
SSE:603259
15.7
6%
2.6
US
Waters Corp
NYSE:WAT
27.6
7%
3.9